Clinical trials: Normal Gait in Children
- Condition Normal Gait in Children
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Hydrocephalus, Hydrocephalus in Children
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
- Trial name
- NCT05397106
- Testing
- CODMAN CERTAS Plus Programmable Valve
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Integra LifeSciences Corporation
Growth Hormone Deficiency in Children
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
The purpose of the study is to investigate the safety and effectiveness of Sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed under real-world clinical practice in…
- Trial name
- NCT06109935
- Testing
- Somapacitan
- Where
- 86 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Idiopathic Short Stature
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
The evaluation of a standardized diagnostic test to predict the growth response in a 1 year trial with Growth Hormone (GH) treatment (carried out in the context of regular patient care) in non GH deficient short children with low…
- Trial name
- NCT01438801
- Testing
- Nutropin [Somatropin (rDNA origin) for injection]
- Sponsor
- Ipsen
Hereditary Angioedema (HAE), Angioedema
Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent angioedema attacks.
- Trial name
- NCT04583007
- Testing
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Where
- 20 sites in United States, Canada and 3 more
- Sponsor
- Shire
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International